Insider Selling: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) COO Sells $73,450.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock opened at $14.02 on Friday. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The firm has a market capitalization of $624.87 million, a price-to-earnings ratio of -28.61 and a beta of 0.66. The stock’s fifty day moving average is $12.23 and its two-hundred day moving average is $13.76.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. As a group, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Cantor Fitzgerald started coverage on shares of Y-mAbs Therapeutics in a research report on Friday, August 16th. They set an “overweight” rating and a $20.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, August 12th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Institutional Trading of Y-mAbs Therapeutics

Large investors have recently modified their holdings of the business. Campbell & CO Investment Adviser LLC purchased a new stake in Y-mAbs Therapeutics in the 4th quarter valued at approximately $562,000. Federated Hermes Inc. raised its holdings in shares of Y-mAbs Therapeutics by 4,708.0% in the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock worth $303,000 after acquiring an additional 43,549 shares during the last quarter. Sapient Capital LLC purchased a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at $298,000. Bailard Inc. acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at $115,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares during the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.